Resource Type: Publication

Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma

By

When Complete Remission is Incomplete

By

Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients with Hematologic Malignancies: A Case-Based Monograph

By

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements

By

Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

By

Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma.

By

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

By

    Opt-in to receive future email communications regarding clonoSEQ

      

    I'm interested in:


    How did you learn about clonoSEQ?

    By checking the “I agree” box, you agree we can send you information about clonoSEQ (you’ll have the option to easily unsubscribe any time) and that you are 18 years of age or older.

    I am a registered user, please take me to the Diagnostic Portal.

    Log In

    I am a new user and need to request a new account

    Request Account

    Please select your location to continue:

    United States Outside the U.S.